In a phase II study, 66 DLBCL patients who received pidilizumab (anti-PD-L1) after autologous hematopoietic stem-cell transplantation (16-month PFS: 0.72) compared favorably with those not receiving pidilizumab after transplantation (18-month PFS: 0.52) from the same population [31]. The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.